Inhibition of ribonucleotide reductase reduces neointimal formation following balloon injury

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 1, 2005, Pages 70-76

  Henry, Jon C ^a   Bonar, Mary M ^a   Kearns, Patrick N ^a   Cui, Hongmei ^b   Mutchler, Megan M ^a   Martin, Michael V ^a   Orsini, Anthony R ^b   Elford, Howard L ^c   Bush, Charles A ^b   Zweier, Jay L ^b   Cardounel, Arturo J ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Molecules for Health Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; DEOXYRIBONUCLEOTIDE; ENZYME INHIBITOR; HYDROXYUREA; IMIDATE; RIBONUCLEOTIDE; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY DILATATION; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; BALLOON; CAROTID ARTERY; CAROTID ARTERY INJURY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; INHIBITION KINETICS; INTIMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT; RESTENOSIS; SMOOTH MUSCLE FIBER;

ANIMALS; BALLOON DILATATION; CELL MOVEMENT; CELL PROLIFERATION; CORONARY RESTENOSIS; CORONARY VESSELS; ENZYME INHIBITORS; FLOW CYTOMETRY; HYDROXAMIC ACIDS; HYDROXYUREA; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR; RIBONUCLEOTIDE REDUCTASES;

EID: 23044469358     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.083980     Document Type: Article

References (51)

1. Anderson HV, Vignale SJ, Benedict CR, and Willerson JT (1993) Restenosis after coronary angioplasty. J Interv Cardiol 6:187-202.
2. Bauters C and Isner JM (1997) The biology of restenosis. Prog Cardiovasc Dis 40:107-116.
3. Bennett MR and O'Sullivan M (2001) Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther 91:149-166.
4. Bhargava B, Karthikeyan G, Abizaid AS, and Mehran R (2003) New approaches to preventing restenosis. BMJ 327:274-279.
5. Crook MF and Akyurek LM (2003) Gene transfer strategies to inhibit neointima formation. Trends Cardiovasc Med 13:102-106.
6. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR, Palasis M, Yang D, Nott SH, and Rogers C (2000) Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 36:2325-2332.
7. Duilio C, Ambrosio G, Kuppusamy P, DiPaula A, Becker LC, and Zweier JL (2001) Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia. Am J Physiol 280:H2649-H2657.
8. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, and Schomig A (1998) Vessel size and long-term outcome after coronary stent placement. Circulation 98:1875-1880.
9. Elford HL (1968) Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 33:129-135.
10. Elford HL (1972) Functional regulation of mammalian ribonucleotide reductase. Adv Enzyme Regul 10:19-38.
11. Elford HL, Freese M, Passamani E, and Morris HP (1970) Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem 245:5228-5233.
12. Elford HL, Wampler GL and van't Riet B (1979) New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res 39:844-851.
13. Epstein SE, Siegall CB, Biro S, Fu YM, FitzGerald D, and Pastan I (1991) Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells. Circulation 84:778-787.
14. Farb A, Weber DK, Kolodgie FD, Burke AP, and Virmani R (2002) Morphological predictors of restenosis after coronary stenting in humans. Circulation 105:2974-2980.
15. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331:496-501.
16. Fritzer-Szekeres M, Grusch M, Luxbacher C, Horvath S, Krupitza G, Elford HL, and Szekeres T (2000) Trimidox, an inhibitor of ribonucleotide reductase, induces apoptosis and activates caspases in HL-60 promyelocytic leukemia cells. Exp Hematol 28:924-930.
17. Fritzer-Szekeres M, Novotny L, Vachalkova A, Findenig G, Elford HL, and Szekeres T (1997) Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase. Life Sci 61:2231-2237.
18. Fritzer-Szekeres M, Salamon A, Grusch M, Horvath Z, Hochtl T, Steinbrugger R, Jager W, Krupitza G, Elford HL, and Szekeres T (2002) Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 64:481-485.
19. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, et al. (2004) Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109:487-493. Epub 2004 Jan 2026.
20. Goldschmidt-Clermont PJ and Moldovan L (1999) Stress, superoxide and signal transduction. Gene Expr 7:255-260.
21. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, and Russell ME (2003) TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107:38-42.
22. Gupta C and Yaffe SJ (1982) Phenobarbital-induced alterations in the sexual differentiation of the female rat: reversal by hydroxyurea and cycloheximide. Pediatr Pharmacol 2:85-91.
23. Heckenkamp J, Gawenda M, and Brunkwall J (2002) Vascular restenosis. Basic science and clinical implications. J Cardiovasc Surg 43:349-357.
24. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, et al. (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103:2289-2295.
25. Horvath Z, Hochtl T, Bauer W, Fritzer-Szekeres M, Elford HL, Szekeres T, and Tihan T (2004) Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells. Cancer Chemother Pharmacol 54:139-145.
26. Inayat MS, Chendil D, Mohiuddin M, Elford HL, Gallicchio VS, and Ahmed MM (2002) Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3. Cancer Biol Ther 1:539-545.
27. Indolfi C, Mongiardo A, Curcio A, and Torella D (2003) Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc Med 13:142-148.
28. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, and Schomig A (2005) Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA (J Am Med Assoc) 293:165-171.
29. Kim JW, Park CG, Seo HS, and Oh DJ (2005) Delayed severe multivessel spasm and aborted sudden death after Taxus stent implantation. Heart 91:e15.
30. Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, Chinen LK, Fuhrhop RW, Scherrer DE, and Wickline SA (2002) Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 106:2842-2847.
31. Lee R, Beauparlant P, Elford H, Ponka P, and Hiscott J (1997) Selective inhibition of l kappaB alpha phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds. Virology 234:277-290.
32. Libby P and Tanaka H (1997) The molecular bases of restenosis. Prog Cardiovasc Dis 40:97-106.
33. Mayhew CN, Phillips JD, Cibull ML, Elford HL, and Gallicchio VS (2002) Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea. Antivir Chem Chemother 13:305-314.
34. Mayhew CN, Phillips JD, Greenberg RN, Birch NJ, Elford HL, and Gallicchio VS (1999) In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity. Stem Cells 17:345-356.
35. Morice M (2005) Eight-month outcome of the reality study: a prospective randomized multi-center head-to-head comparison of the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus). J Am Coll Cardiol 45.
36. Natsumeda Y, Lui MS, Emrani J, Faderan MA, Reardon MA, Eble JN, Glover JL, and Weber G (1985) Purine enzymology of human colon carcinomas. Cancer Res 45:2556-2559.
37. Noda-Heiny H and Sobel BE (1995) Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. Am J Physiol 268:C1195-C1201.
38. Pacelli R, Taira J, Cook JA, Wink DA, and Krishna MC (1996) Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet 347:900.
39. Sarkar R, Gordon D, Stanley JC, and Webb RC (1997) Cell cycle effects of nitric oxide on vascular smooth muscle cells. Am J Physiol 272:H1810-H1818.
40. Sarkar R and Webb RC (1998) Does nitric oxide regulate smooth muscle cell proliferation? A critical appraisal. J Vasc Res 35:135-142.
41. Segev A, Aviezer D, Safran M, Gross Z, and Yayon A (2002) Inhibition of vascular smooth muscle cell proliferation by a novel fibroblast growth factor receptor antagonist. Cardiovasc Res 53:232-241.
42. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, et al. (2001) Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103:192-195.
43. Stolze K and Nohl H (1990) EPR studies on the oxidation of hydroxyurea to paramagnetic compounds by oxyhemoglobin. Biochem Pharmacol 40:799-802.
44. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, et al. (2004) One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109:1942-1947.
45. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, et al. (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188-1193.
46. Takeda E and Weber G (1981) Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci 28:1007-1014.
47. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, and Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature (Lond) 404:42-49.
48. Turchan J, Pocernich CB, Gairola C, Chauhan A, Schifitto G, Butterfield DA, Buch S, Narayan O, Sinai A, Geiger J, et al. (2003) Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 60:307-314.
49. Ueda M, Becker AE, Naruko T, and Kojima A (1995) Smooth muscle cell dedifferentiation is a fundamental change preceding wound healing after percutaneous transluminal coronary angioplasty in humans. Coron Artery Dis 6:71-81.
50. Vaughan WP, Holm C, and Cordel K (1989) Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4′-(9-acridinylamino) methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model. Cancer Chemother Pharmacol 23:26-30.
51. Ward MR, Pasterkamp G, Yeung AC, and Borst C (2000) Arterial remodeling. Mechanisms and clinical implications. Circulation 102:1186-1191.